Evidence map›Paper›PMID 35405261›Full record

ReviewNeurobiology of disease2022

The Cure VCP Scientific Conference 2021: Molecular and clinical insights into neurodegeneration and myopathy linked to multisystem proteinopathy-1 (MSP-1).

Michelle A Johnson, Jacob A Klickstein, Richa Khanna, Yunzi Gou, Cure VCP Disease Research Consortium, Malavika Raman

Abstract readReview
In one paragraph

Review in Neurobiology of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Targeting mitophagy in neurodegenerative diseases.Nature reviews. Drug discovery · 2025
    Review
  5. Article
  6. Review
  7. Visualization of the Cdc48 AAA+ ATPase protein unfolding pathway.bioRxiv : the preprint server for biology · 2023
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michelle A JohnsonDepartment of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States of America.
Jacob A KlicksteinDepartment of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States of America.
Richa KhannaDepartment of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States of America.
Yunzi GouDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA, United States of America.
Cure VCP Disease Research Consortium
Malavika RamanDepartment of Developmental Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States of America. Electronic address: malavika.raman@tufts.edu.

Funding

Tufts IRACDAK12GM133314 · NIGMS · TUFTS UNIVERSITY BOSTON · PI CLAIRE L MOORE, Jamie Lynn Maguire · 2019 to 2026
$8.4M
“Regulation of Protein Quality Control by the VCP AAA-ATPase”R01GM127557 · NIGMS · TUFTS UNIVERSITY BOSTON · PI Malavika Raman · 2018 to 2026
$3.5M
Visualizing the Mechanisms of Protein Quality ControlR35GM133772 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Peter Shen · 2019 to 2026
$3.4M
Investigating the impact of p97 mutation in Amyotrophic Lateral SclerosisR21NS123631 · NINDS · TUFTS UNIVERSITY BOSTON · PI RAMAN, MALAVIKA · 2022 to 2023
$454k
NIGMS NIH HHS K12 GM133314NIGMS NIH HHS R01 GM127557NIGMS NIH HHS R35 GM133772NINDS NIH HHS R21 NS123631
6 · The paper itself

Abstract

The 2021 VCP Scientific Conference took place virtually from September 9-10, 2021. This conference, planned and organized by the nonprofit patient advocacy group Cure VCP Disease, Inc. (https://www.curevcp.org), was the first VCP focused meeting since the 215th ENMC International Workshop VCP-related multi-system proteinopathy in 2016 (Evangelista et al., 2016). Mutations in VCP cause a complex and heterogenous disease termed inclusion body myopathy (IBM) with Paget's disease of the bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), or multisystem proteinopathy 1 (MSP-1) Kimonis (n.d.), Kovach et al. (2001), Kimonis et al. (2000). In addition, VCP mutations also cause other age-related neurodegenerative disorders including amyptrophic lateral sclerosis (ALS), Parkinsonism, Charcot-Marie type II-B, vacuolar tauopathy among others (Korb et al., 2022). The objectives of this conference were as follows: (1) to provide a forum that facilitates sharing of published and unpublished information on physiological roles of p97/VCP, and on how mutations of VCP lead to diseases; (2) to bolster understanding of mechanisms involved in p97/VCP-relevant diseases and to enable identification of therapeutics to treat these conditions; (3) to identify gaps and barriers of further discoveries and translational research in the p97/VCP field; (4) to set a concrete basic and translational research agenda for future studies including crucial discussions on biomarker discoveries and patient longitudinal studies to facilitate near-term clinical trials; (5) to accelerate cross-disciplinary research collaborations among p97/VCP researchers; (6) to enable attendees to learn about new tools and reagents with the potential to facilitate p97/VCP research; (7) to assist trainees in propelling their research and to foster mentorship from leaders in the field; and (8) to promote diversity and inclusion of under-represented minorities in p97/VCP research as diversity is critically important for strong scientific research. Given the range of topics, the VCP Scientific Conference brought together over one hundred and forty individuals representing a diverse group of research scientists, trainees, medical practitioners, industry representatives, and patient advocates. Twenty-five institutions with individuals from thirteen countries attended this virtual meeting. In this report, we summarize the major topics presented at this conference by a range of experts.

Indexed as

Frontotemporal DementiaMyositis, Inclusion BodyCell Cycle ProteinsHumansMerozoite Surface Protein 1Muscular Dystrophies, Limb-GirdleMutationOsteitis DeformansValosin Containing ProteinCell Cycle ProteinsMerozoite Surface Protein 1Valosin Containing ProteinVCP protein, humanAmyotrophic lateral sclerosisAutophagyClinical trialFrontotemporal dementiaInclusion body myopathyInhibitorMotor neuron diseasep97Paget's disease of the boneProteinopathyUbiquitinVCP

Identifiers

PMID35405261
PMCPMC9169230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.